Sanofi India declares 8% growth in net sales for Q4-2024
Standalone profit from operations for Q4-2024 were Rs. 108 crore
Standalone profit from operations for Q4-2024 were Rs. 108 crore
Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain
YESINTEK is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis
Collaborates with VisionSpring to conduct eye check-up camps for underprivileged children
Dr. Prabhavathi brings over 14 years of unparalleled experience in pediatrics and a specialized focus on neurodevelopmental disorders
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries
Peter Bains has over three decades of experience in the biotech and pharmaceutical industry
Pascal Villemagne has announced his intent to step down at the end of March 2025, to take on a new challenge in his professional career.
Subscribe To Our Newsletter & Stay Updated